RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
CGene Tech, a Suzhou BioBay novel small molecule drug developer, raised $14.5 million in a Series A+ financing, led by Hongtai Capital with ABC International participating. CGene’s lead candidate is an innovative cetagliptin phosphate DPP-4 inhibitor for type 2 diabetes that has completed a Phase I trial in China. CGene said it would use the proceeds from the round to advance the clinical program for its hypoglycemic drug and support development of its oncology candidates and generic drugs for rare diseases. Source: China Biotoday
